Following a December 2025 executive order, the Justice Department issued an April 23, 2026 order moving FDA-approved and state-licensed medical cannabis into Schedule III—leading to summer 2026 DEA hearings and the first…
Signed into law on December 20, 2018 after overwhelming bipartisan votes in Congress, the Agriculture Improvement Act of 2018 federally descheduled cannabis plants and derivatives containing no more than 0.3% delta-9 THC…
On June 25, 2018, the U.S. Food and Drug Administration approved Epidiolex—an oral cannabidiol (CBD) solution for rare childhood epilepsy syndromes—forcing the DEA to reschedule a plant-derived cannabinoid for the first time.
Signed into law on December 16, 2014 after passing the House 219–189, the bipartisan spending rider prohibited the Justice Department from using federal funds to interfere with state medical marijuana laws.
On August 29, 2013, Deputy Attorney General James Cole instructed federal prosecutors to deprioritize cannabis businesses complying with strict state laws unless they violated eight federal priorities.
In a landmark 6–3 constitutional decision on June 6, 2005, the U.S. Supreme Court ruled that the federal Controlled Substances Act applies even to California medical patients growing cannabis at home strictly…
Signed on October 27, 1970, the Controlled Substances Act replaced the 1937 Marihuana Tax Act and placed cannabis in Schedule I alongside heroin and LSD.